Avian influenza virus as a human pandemic threat factor
Keywords:
avian influenza, humansAbstract
In the paper avian influenza virus biological properties, as well as pathogenicity for animals and humans, clinical syndromes and methods of avian influenza detection, diagnosis, treatment and prevention have been presented.
Downloads
References
Horimoto T., Kawaoka Y., Pandemic threat posed by avian influenza A viruses, Clin. Microb.Rev. 2001; 14(1), 129.
Trampuz A., Prashu R., Smith T., Baddour L.: Avian influenza: a new pandemic threat?, Mayo Clin.Proc. 2004, 79, 523.
Beigel J.H., Farrar J., Han. A.M., Hayden F.G., Hyer R., De Jong M.D. i wsp.: Avian influenza (H5N1) infection in humans, N.Eng.J.Med.; 2005, 353 (13): 1374.
Nicholson K.G., Wood J.M., Zambon M., Influenza, Lancet 2003; 362: 1733.
Chan P.K.: Outbreak of avian influenza A (H5N1) virus infection in Hong Kong in 1997, Clin.Infect.Dis.; 2002, 34 (Suppl 2), 58.
Centres for Disease Control and Prevention. Avian Influenza, www.cdc.gov/flu/avian/index.htm.
Mounts A.W., Kwong H., Izurieta H.S., Bridges C.B., Lim W., Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong 1997–1998, J.Infect.Dis. 1999; 180: 505.
Koopmans M., Wilbrink B., Conyn M., Transmission of H7N7 avian influenza: A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands, Lancet. 2004; 363: 597
Liu J., Xiao H., Lei F., Zhu Q., Qin K, Hang X.W. i wsp.: Highly pathogenic H5N1 influenza virus infection in migratory birds, Science. 2005; 309: 1206.
Subburao K., Klimov A., Katz J., Regnery H., Lim W., Hall H. i wsp., Characterization of an avian influenza: A (H5N1) virus isolated from a child with a fatal respiratory illness, Science, 1998, 279 (1): 393.
Hayden F., Croisier A., Transmission of avian influenza viruses to and between humans, J.Infect.Dis. 2005, 192 (19): 1311.
Stegeman A., Bouma A., Elbers A.R., de Jong M.C., Nodeljijk G., de Klerk F. I in: Avian influenza: A virus H7N7 epidemic in The Netherlands in 2003: course of the epidemic and effectiveness of control measures, J.Infect.Dis. 2004; 190 (12): 2088.
World Health Organization. Avian Influenza – www.who.int./csr/disease/avian_influenza/en/
Yuen K.Y., Chan P.K., Peiris M., Liem N.T.,: Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet, 1998: 351: 467.
Hatta M., Gao P., Halfmann P., Kawaoka Y, Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses, Science 2001; 293: 1840.
Shinya K., Hatta M., Yamada S., Takada A., Watanabe S., Halmann P. i wsp., Characterization of a human virus H5N1 influenza A isolated in 2003. J.Virol. 2005; 79: 9926.
Cheung C.Y., Poon L.L., Lau A.S., Seo S.H., Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?, Lancet 2002; 360: 1831.
Keawcharoen J., Oraveerakul K., Kuiken T., Rimmelzwaan G., Riel D., Avian influenza H5N1 in tigers and leopards, Emerg.Infect.Dis. 2004; 10: 2189.
Hien T.T., Lien L.T., Dung N.T., Lim.W., Avian influenza A (H5N1) in 10 patients in Vietnam, N.Eng.J.Med. 2004; 350: 1179.
Bridges C.B., Kuehnert M.J., Hall C.B., Transmission of influenza: implications for control in health care settings, Clin.Infect.Dis. 2003; 37: 1094.
Ungchusak K., Auewarakul P., Dowell S.F., Dong V.C., Chau N.V.V., Probable person-to person transmission of avian influenza A (H5N1), N.Eng.J.Med.; 2005; 352: 333.
Katz J.M., Lim W., Bridges C.B., Buxton B.C., Seto W.H., Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among haushold and social contacts, J.Infect,Dis. 1999;180: 1763 – 70
Boivin G., Cote S., Dery P., De Serres G., Bergeron M.G., Multiplex real-time PCR assay for detection of influenza and human respiratory syncytial viruses, J.Clin.Microbiol. 2004;42: 45.
Salgado C.D., Farr B.M., Hall K.K., Hayden F.G., Influenza in the acute hospital setting, Lancet Infect. Dis. 2002; 2: 145.
Gubareva L.V., Kaiser L., Hayden F.G.: Influenza virus neuraminidase inhibitors, Lancet. 2000; 355: 827 – 835
Treanor J.J., Hayden F.G., Vrooman P.S., Coopper N.J., Sutton A.J., Abrams K.R., i wsp., Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000; 283: 1016.
Treanor J.J., Wilkinson B.E., Masseoud F., Nicholson K.G., Colegate A.E, Safety and immunogenicity of recombinant hemagglutinin vaccine for H5 influenza in humans, Vaccine 2001; 19:1731.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2006 Medical Journal of the Rzeszow University
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
